Evidence map›Paper›PMID 32592066›Full record

ArticleJournal of cancer research and clinical oncology2020

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma.

Florian Gebauer, Max Krämer, Christiane Bruns, Hans A Schlößer, Martin Thelen, Philipp Lohneis, Wolfgang Schröder, Thomas Zander, Hakan Alakus, Reinhard Buettner and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. LAG3 in gastric cancer: it's complicated.Journal of cancer research and clinical oncology · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Florian GebauerDepartment of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany. florian.gebauer@uk-koeln.de.ORCID http://orcid.org/0000-0001-5312-4814
Max KrämerInstitute of Pathology, University of Cologne, Cologne, Germany.
Christiane BrunsDepartment of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Hans A SchlößerDepartment of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Martin ThelenDepartment of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Philipp LohneisInstitute of Pathology, University of Cologne, Cologne, Germany.
Wolfgang SchröderDepartment of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Thomas ZanderDepartment I of Internal Medicine, Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Gastrointestinal Cancer Group Cologne GCGC, University of Cologne, Cologne, Germany.
Hakan AlakusDepartment of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Reinhard BuettnerInstitute of Pathology, University of Cologne, Cologne, Germany.
Heike LoeserInstitute of Pathology, University of Cologne, Cologne, Germany.
Alexander QuaasInstitute of Pathology, University of Cologne, Cologne, Germany.
University of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLymphocyte activation gene-3 (LAG3) is an immunosuppressive checkpoint molecule expressed on T cells. The frequency and distribution of LAG3 expression in oesophageal adenocarcinoma (EAC) is unknown. Aim of the study was the evaluation and distribution of LAG3 on tumour infiltrating lymphocytes (TILs) and correlation with clinico-pathological and molecular data.

methodsWe analysed tumor tissue samples using immunohistochemistry, multi-colour immunofluorescence and mRNA in-situ technology. The analyses were performed on a multi-spot tissue microarray (TMA) with 165 samples, followed by an evaluation on a single-spot TMA with 477 samples. These results were correlated with clinical and molecular tumour data.

resultsLAG3 expression on TILs was detectable in 10.5% on the multi-spot TMA and 11.4% on the single-spot TMA. There was a strong correlation between protein expression and mRNA expression (p < 0.001) in TILs. LAG 3 expression was correlated with CD4+ and CD8+ T-cells within the tumor (p < 0.001). LAG3 expression showed an improved overall survival (OS) compared to patients without LAG3 expression (median OS 70.2 vs. 26.9 months; p = 0.046). The effect was even clearer in the group of patients with tumour stages > pT2 (70.2 vs 25.0 months; p = 0.037).

conclusionThis is the first description of LAG3 expression on TILs in EAC, underscoring the importance of immunomodulation in EAC. Our data suggest an impact of LAG3 in a relevant subset of EAC. Therapeutic studies investigating the efficacy of LAG3 inhibition in EAC will also provide predictive evidence and relevance of the immunohistochemical determination of LAG3 expression.

Indexed as

AdenocarcinomaAgedAntigens, CDCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEsophageal NeoplasmsFemaleHumansLymphocyte ActivationLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMaleNeoplasm StagingRNA, MessengerAntigens, CDLag3 protein, humanLymphocyte Activation Gene 3 ProteinRNA, MessengerImmunohistochemistryLAG3mRNA in-situOesophageal adenocarcinoma

Identifiers

PMID32592066
PMCPMC7382658
OpenAlexW3037726725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.